The broader market weakness spread into the biotech sector in the week ending Jan. 28, sending stocks lower.
Johnson & Johnson got the ball rolling on large-cap biopharma earnings, with mixed results. The positive forward outlook, however, lent support to the stock. Edwards Lifesciences Corporation came under pressure following an earnings miss.
